A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer

Administered By

Awarded By

Contributors

Start/End

  • July 11, 2018 - April 30, 2022